The recent surge in consumer demand for GLP-1 receptor agonists like semaglutide and tirzepatide has given rise to a booming telemedicine industry offering compounded alternatives to brand-name drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. However, this rapid expansion has triggered significant regulatory scrutiny. In a coordinated enforcement action, the U.S. Food and Drug Administration (FDA) issued a wave of warning letters to numerous online retailers and telemedicine companies and has even decided to refer cases to the Department of Justice for enforcement. These letters outline critical violations of the Federal Food, Drug, and Cosmetic Act (FDCA), highlighting systemic issues in how these compounded drugs are marketed and sold.
For industry stakeholders, understanding these violations is crucial. The FDA’s citations center on four primary areas:
Misleading use of “generic” terminology,
False claims of FDA approval,
Illegal sale of unapproved new drugs (specifically retatrutide), and
Misbranding regarding safety and efficacy.
The “Generic” Illusion and Misleading Comparisons
A predominant issue cited across almost all warning letters is the marketing of compounded drugs as “generic” versions of FDA-approved brand-name medications. Companies frequently used phrases such as “Generic Ozempic,” “Semaglutide is the generic drug in Ozempic,” or “generic version of Mounjaro”.
The FDA firmly rejects this characterization. Compounded drugs are not FDA-approved generics; they have not undergone the rigorous premarket review for safety, efficacy, and quality that generic drugs must pass. By labeling these products as “generic” or claiming they are “substitutes,” companies create the false impression that the compounded product is identical to the approved drug.
Furthermore, many companies were flagged for stating their products contain the “same active ingredient” as brand-name drugs, such as “Same active ingredient as Wegovy and Ozempic”. The FDA asserts that such claims are false or misleading because they imply the compounded drug product itself is the same as the FDA-approved product, which is not the case. These comparisons minimize the distinct risks associated with compounded formulations, which do not have FDA-approved labeling or manufacturing oversight.
The “FDA-Approved” Deception
Several telemedicine platforms explicitly claimed their compounded medications were “FDA-Approved” or “FDA-Approved Medication”. Others attempted to borrow legitimacy by stating their products were made with “FDA-approved ingredients” in a way that implied the final product was approved.
The FDA’s position is clear: compounded drug products are not FDA-approved. Asserting otherwise constitutes misbranding under section 502(a) of the FDCA. Even if the bulk drug substance used in compounding is made at an FDA-registered facility, the final compounded dosage form has not been evaluated by the agency. Claims that “FDA-approved ingredients” equate to a safe, approved final product are considered deceptive marketing that misleads consumers regarding the regulatory status of the drug they are purchasing.
The Retatrutide Problem: Unapproved New Drugs
While semaglutide and tirzepatide are components of FDA-approved drugs (and thus generally eligible for compounding exemptions under specific conditions), the FDA identified a distinct violation regarding retatrutide. Multiple companies were warned for selling compounded retatrutide products.
The FDA noted that retatrutide is not the subject of a United States Pharmacopeia (USP) or National Formulary (NF) monograph, is not a component of an FDA-approved human drug, and does not appear on the “503A bulks list”. Consequently, compounded retatrutide does not qualify for the statutory exemptions allowed for compounded drugs. This renders any compounded product containing retatrutide an “unapproved new drug.” Introducing these products into interstate commerce is a direct violation of section 505(a) of the FDCA. Accordingly, while compounding semaglutide may be permissible under shortages, compounding retatrutide is illegal under current regulations.
Unsubstantiated “Clinically Proven” Claims
Finally, companies marketed their specific products with phrases like “Clinically Proven Weight Loss” or “Clinically proven success”. The FDA flagged these as false or misleading because the compounded versions themselves have never been evaluated in clinical trials. Relying on data from brand-name drug trials to substantiate claims for a compounded formulation is impermissible, as differences in formulation, pharmacokinetics, and bioavailability can significantly alter safety and efficacy.
The FDA further cited these products for misbranding under section 502(f)(1) because they failed to bear “adequate directions for use” because these are prescription drugs intended for conditions which cannot be not amenable to self-diagnosis (like obesity and diabetes), adequate directions cannot be written for a layperson, mandating professional supervision that was often lacking in the direct-to-consumer model presented.
Conclusion
The FDA’s recent enforcement actions send a clear message to the telemedicine and compounding industry that the agency is actively policing the boundary between legitimate compounding and the marketing of unapproved new drugs. Claims that blur the lines between compounded drugs and FDA-approved generics, imply non-existent FDA approval, or sell substances like retatrutide that fall outside regulatory exemptions will face strict enforcement. Telemedicine providers must rigorously review their marketing materials to ensure they must accurately reflect the regulatory status of their products, avoiding terms like “generic,” “FDA-approved,” and unsubstantiated clinical claims to remain in compliance.
For help with complying with FDA expectations and avoiding DOJ scrutiny, please contact Darshan Kulkarni PharmD, MS, Esq. at the Kulkarni Law Firm, PC at 302.252.6959 or by visiting www.kulkarnilawfirm.com.
Related reading: Explore more coverage in our Legal section and browse the latest analysis on Dispense Times.
